Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Энректиниб как монопрепарат в первичной терапии детей

2 ноября 2026 г. обновлено: St. Jude Children's Research Hospital

ФАЗА 2 Исследование энтректиниба в качестве монопрепарата в начальной терапии детей

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

Обзор исследования

Подробное описание

PRIMARY OBJECTIVE

  • To determine the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) (Cohort 1).

SECONDARY OBJECTIVES

  • To estimate the 2-year and 5-year progression free survival (PFS) and overall survival (OS) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused HGG treated who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 1).
  • To describe the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG (Cohort 2).
  • To estimate the 2-year and 5-year PFS and OS in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 2).
  • To describe toxicities experienced by patients younger than 3 years of age treated with entrectinib (Cohort 1 and 2).
  • To evaluate number of patients that are screened for the study and eligible versus enrolled and treated with entrectinib (Cohort 1 and 2).
  • To measure the time intervals (days) from time of initial diagnostic surgery to screening and enrollment in this study (Cohort 1 and 2).

The trial will have 2 cohorts: Cohort 1: patients diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) and Cohort 2: patients diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG.

Patients receive entrectinib enterally once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients requiring bridging therapy prior to starting entrectinib may receive cyclophosphamide intravenously (IV) over 1 hour on day 1, etoposide IV over 1 hour on day 1 and 2, carboplatin IV over 1 hour on day 2, filgrastim subcutaneously (SC) or IV or pegfilgrastim SC on day 3.

A gross total resection or significant debulking may become possible if a response to entrectinib is seen. If surgical resection is performed and a gross total resection is achieved, 24 cycles of entrectinib will be completed, including those before and after surgery.

After treatment, patients will be followed for 5 years.

Тип исследования

Интервенционный

Регистрация (Оцененный)

52

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Tabatha E. Doyle, RN
  • Номер телефона: 901-595-2544
  • Электронная почта: tabatha.doyle@stjude.org

Учебное резервное копирование контактов

  • Имя: Daniel Moreira, MD, MEd
  • Номер телефона: 901-585-1911
  • Электронная почта: daniel.moreira@stjude.org

Места учебы

      • São Paulo, Бразилия, 08270-070
        • Рекрутинг
        • Hospital Santa Marcelina
        • Главный следователь:
          • Sidnei Epelman, MD
        • Контакт:
          • Sidnei Epelman, MD
          • Номер телефона: +55 11 2522-2472
          • Электронная почта: epelman@inctrbrasil.org
      • São Paulo, Бразилия, 04039-001
        • Рекрутинг
        • GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
        • Контакт:
        • Главный следователь:
          • Andrea M. Cappellano, MD
    • São Paulo
      • Barretos, São Paulo, Бразилия, 14784400
        • Рекрутинг
        • Hospital de Câncer de Barretos
        • Контакт:
          • Thais J. Vampre, MD
          • Номер телефона: 17 3321-6647
          • Электронная почта: thaisjunq79@gmail.com
        • Главный следователь:
          • Thais J. Vampre, MD
      • Amman, Иордания, 11941
        • Рекрутинг
        • King Hussein Cancer Center
        • Контакт:
          • Nisreen Amayiri, MD
          • Номер телефона: 6376 (962 6) 5300460
          • Электронная почта: namayiri@khcc.jo
        • Главный следователь:
          • Nisreen Amayiri, MD
      • Lima, Перу
        • Рекрутинг
        • Instituto Nacional de Enfermedades Neoplásicas
        • Контакт:
          • Rosdali Coronado, MD
          • Номер телефона: +51 991765893
          • Электронная почта: rosdali.diaz.c@upch.pe
        • Главный следователь:
          • Rosdali Coronado, MD
    • Tennessee
      • Memphis, Tennessee, Соединенные Штаты, 38105
        • Рекрутинг
        • St. Jude Children's Research Hospital
        • Контакт:
          • Tabatha E. Doyle, RN
          • Номер телефона: 901-595-2544
          • Электронная почта: tabatha.doyle@stjude.org
        • Главный следователь:
          • Daniel Moreira, MD, MEd
        • Контакт:

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

Не старше 3 года (Ребенок)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria: Screening Phase

  • Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)
  • Participant with presumed newly diagnosed tumor in the supratentorial compartment
  • Patient must have measurable disease based on RAPNO criteria
  • ≤84 days since surgery (resection or biopsy)
  • Available tumor tissue for central review
  • Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines

Exclusion Criteria: Screening Phase

  • Previous exposure to cytotoxic chemotherapy or radiotherapy

Inclusion Criteria: COHORT 1

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • High-grade glioma (World Health Organization [WHO] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)

  • Absolute neutrophil count >1,000/µL

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Inclusion Criteria: COHORT 2

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment.

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);

  • Absolute neutrophil count >1,000/µL.

  • ALT and ALT ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Exclusion Criteria: COHORT 1 AND 2

  • Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history
  • History of recent (3 months) symptomatic congestive heart failure
  • Known active, uncontrolled infection (bacterial, fungal, or viral)
  • Receiving enzyme inducing antiepileptic drugs (EIAEDs)
  • Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation
  • Receiving another investigational agent concurrently
  • Surgery within 2 weeks prior to treatment enrollment
  • Patients with known hypersensitivity to excipients of the investigational medicinal product
  • Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption
  • Inability to take medication enterally

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Н/Д
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Entrectinib therapy, Cohort 1 and Cohort 2

Cohort 1: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) will receive therapy as outline in Detailed Description.

Cohort 2: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG will receive therapy as outline in Detailed Description.

Given IV

Другие имена:
  • Параплатин®

Given IV

Другие имена:
  • ВП-16

Given orally (PO) or enterally

Другие имена:
  • Розлытрек

Given intravenous (IV)

Другие имена:
  • Цитоксан®

Given subcutaneous (SQ) or IV

Другие имена:
  • Филграстим

Given SQ as part of recommended Bridging Therapy instead of G-CSF.

Другие имена:
  • Неласта

A gross total resection or significant debulking may become possible if a response to entrectinib is seen.

Другие имена:
  • Хирургическая резекция

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall response rate (ORR) (Cohort 1)
Временное ограничение: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Progression free survival (PFS) (Cohort 1)
Временное ограничение: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
Overall survival (OS) (Cohort 1)
Временное ограничение: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
Duration of response (DOR) (Cohort 1)
Временное ограничение: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 1)
Временное ограничение: Up to 5 years

Percentage of patients who had second surgeries.

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 1)
Временное ограничение: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
ORR (Cohort 2)
Временное ограничение: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).
PFS (Cohort 2)
Временное ограничение: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
OS (Cohort 2)
Временное ограничение: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
DOR (Cohort 2)
Временное ограничение: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 2)
Временное ограничение: Up to 5 years

Percentage of patients who had second surgeries. [Time Frame: Up to 5 years]

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 2)
Временное ограничение: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
Incidence of adverse events (Cohort 1 and 2)
Временное ограничение: Up to 5 years

Percentage of adverse events on therapy including Entrectinib, captured using National Cancer Institute Common Terminology Criteria for Adverse Events 5.0.

Up to 5 years
Number of patients screened versus enrolled and treated (Cohort 1 and 2)
Временное ограничение: Up to 5 years

Number of enrolled and treated patients as a percentage of number of patients screened and eligible for study.

Up to 5 years
Time from initial diagnostic surgery to screening and enrollment (Cohort 1 and 2)
Временное ограничение: Up to 5 years

Median time in days from initial surgery to screening and enrollment on study.

Up to 5 years

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Соавторы

Следователи

  • Главный следователь: Daniel Moreira, MD, MEd, St. Jude Children's Research Hospital

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

1 мая 2026 г.

Первичное завершение (Оцененный)

1 ноября 2027 г.

Завершение исследования (Оцененный)

1 ноября 2032 г.

Даты регистрации исследования

Первый отправленный

22 июля 2024 г.

Впервые представлено, что соответствует критериям контроля качества

25 июля 2024 г.

Первый опубликованный (Действительный)

30 июля 2024 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

3 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

2 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • GLOBOTRK
  • NCI-2024-02977 (Идентификатор реестра: NCI Clinical Trial Registration Program)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Сроки обмена IPD

Data will be made available at the time of article publication.

Критерии совместного доступа к IPD

Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП
  • МКФ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться